Hydrocision
HydroCision develops and markets proprietary FluidJet-based minimally invasive surgical devices—TenJet for tendinopathy, SpineJet for discectomy, and AlloJet for allograft preparation—selling directly to orthopedic surgeons, spine specialists, and tissue banks while licensing its core technology to partners like PROCEPT BioRobotics and Smith & Nephew.
- Company typePrivate
- Founded1994
- HeadquartersNorth Billerica, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Hydrocision does
HydroCision is a privately held medical device company founded in 1994 and headquartered in North Billerica, Massachusetts, that develops, manufactures, and markets fluid jet-based surgical tools for minimally invasive spine and orthopedic procedures. The company's proprietary FluidJet technology delivers a high-velocity stream of sterile saline that simultaneously cuts and aspirates tissue via a Venturi suction effect, operating non-thermally to avoid collateral tissue damage and enabling selective resection of pathologic tissue while sparing healthy structures. Its commercial portfolio comprises three products built on a shared power console platform: TenJet for chronic tendinopathy and tenotomy procedures, SpineJet for percutaneous discectomy in contained lumbar disc herniations, and AlloJet for bone allograft preparation in tissue banks. The company also licenses its core pump cartridge and fluid-jet technology to third parties, including an exclusive worldwide urology license to PROCEPT BioRobotics (Aquablation therapy for BPH, used in PROCEPT's 2021 IPO) and an exclusive wound-care license to Smith & Nephew, generating upfront payments and ongoing royalties.
The business operates a sales-led, direct sales model with dedicated sales representatives for each product line, targeting orthopedic surgeons, sports medicine physicians, podiatrists, pain management specialists, and tissue banks across the United States, supported by a sales portal, physician finder tool, and clinical education programs (TenJet Sports Medicine Physicians Group, monthly webinars). Revenue is generated through hardware sales of consoles and recurring single-use handpieces, procedure reimbursement from Medicare and private insurers, and technology licensing royalties. The company employs 11-50 people, is backed by investors including Volcano Capital, BioVentures Investors, and Omega Funds, and has been led since 2019 by a series of commercial-experienced CEOs (most recently Rick Lytle, formerly of Covidien and ArjoHuntleigh). HydroCision's IP moat rests on a patent estate including US Patent 11,278,305 covering selective tendon tissue removal, and FDA clearances across multiple clinical applications.
Hydrocision firmographics
Firmographics- Name
- Hydrocision
- Legal name
- HydroCision, Inc.
- Website
- https://hydrocision.com
- Company type
- Private
- Founded year
- 1994
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- HydroCision develops and markets proprietary FluidJet-based minimally invasive surgical devices—TenJet for tendinopathy, SpineJet for discectomy, and AlloJet for allograft preparation—selling directly to orthopedic surgeons, spine specialists, and tissue banks while licensing its core technology to partners like PROCEPT BioRobotics and Smith & Nephew.
- Ownership category
- akta.pro rank
Hydrocision industry classification
Industry- Product category
- Minimally Invasive Surgical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- akta.pro primary industry
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)
- akta.pro secondary industries
- Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Suction, Irrigation & Fluid Management Systems (HLAHADAK)
Keywords
Where Hydrocision is headquartered
LocationHeadquarters
- HQ city
- North Billerica
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Hydrocision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations
Revenue model
- Medical Device Sales: HydroCision generates revenue through the sale of its proprietary medical devices including the Series-82 and Series-52 consoles, single-use handpieces (TenJet, SpineJet, AlloJet), and accessories. The company sells directly to healthcare providers and hospitals.
- Technology Licensing: HydroCision licenses its FluidJet technology to other medical device companies. Notable licenses include exclusive worldwide license to PROCEPT BioRobotics for urology applications and to Smith & Nephew for wound care applications. Receives upfront payments and ongoing royalties from licensees.
- Procedure Reimbursement: The tenotomy procedure using TenJet is reimbursed by Medicare and most private insurers. SpineJet HydroDiscectomy procedures are also covered by insurance, varying by insurer and plan.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Transaction based/ take rate | Pay-as-you-go | Insurance Reimbursement |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Hydrocision product offering
Product offeringCore offering
HydroCision develops, manufactures, and markets minimally invasive surgical devices powered by its proprietary FluidJet technology — a high-velocity, non-thermal sterile saline stream that simultaneously cuts and aspirates targeted tissue. Its commercial product lines include the TenJet tenotomy device for chronic tendon conditions, the SpineJet PercResector for percutaneous discectomy, and the AlloJet allograft debridement system for tissue banks, sold primarily to hospitals and specialists in the United States. The company also licenses its core fluid-jet technology to partners in urology and wound care.
Product overview
HydroCision is a medical device company offering a portfolio of FluidJet technology-based surgical devices. The core platform consists of high-velocity water jet technology that uses pressurized saline for tissue resection without thermal damage. Three main commercial products serve distinct clinical applications: TenJet for orthopedic/tendon treatments in sports medicine, SpineJet for spinal discectomy procedures, and AlloJet for bone allograft tissue preparation. Each product uses customized single-use handpieces designed for specific clinical applications while sharing the common FluidJet power console technology.
Differentiator
Problem solved
Functional benefit
Brands
- TenJet: Minimally invasive tenotomy device for treatment of chronic tendinopathy and tendon pain using high-velocity saline jet technology.
- SpineJet
- AlloJet
- FluidJet
Products and services
- TenJet Tenotomy Device Minimally invasive tenotomy device using high-velocity saline jet technology to selectively resect and remove diseased tendon tissue while sparing healthy tissue. Treats chronic tendinosis, calcific tendinitis, tennis elbow, golfer's elbow, Achilles tendinosis, plantar fasciitis, and other tendon conditions for orthopedic and sports medicine physicians.
- SpineJet PercResector Percutaneous decompression device using a non-thermal fluid-jet system for treating contained lumbar disc herniations. The 4.0 mm cannulated access set creates a minimally invasive pathway through Kambin's triangle for disc tissue removal in discectomy procedures performed by neurosurgeons, orthopedic spine surgeons, and pain management specialists.
- AlloJet Allograft Debridement System Bone allograft preparation device using a 500 mph high-velocity fluidjet to safely and effectively remove soft tissue from donor bones. Enables sterile cleaning of bone allografts with increased yield and reduced workplace injuries, sold to musculoskeletal tissue banks and tissue processing facilities.
- Series-82 and Series-52 FluidJet Power Consoles Capital equipment component of the FluidJet platform. Power consoles deliver pressurized sterile saline at adjustable settings through high-pressure tubing into single-use handpieces (TenJet, SpineJet, AlloJet), generating the high-velocity non-thermal cutting jet that resects and aspirates targeted tissue in a single action.
Quantifiable outcome
- 94% improvement in back and leg pain for patients receiving HydroDiscectomy procedure (multi-center study, 50 patients)
- +4 more outcomes
Companies that use Hydrocision
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Hydrocision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Hydrocision partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- PROCEPT BioRoboticscoreHydroCision granted PROCEPT BioRobotics an exclusive worldwide license of its pump cartridge technology for use in urology. PROCEPT uses this technology with their AquaBeam Robotic System for Aquablation therapy - the first surgical robot providing autonomous tissue removal for BPH treatment. PROCEPT subsequently completed an IPO in November 2021.
- Smith & NephewcoreHydroCision previously granted Smith & Nephew an exclusive license for use of FluidJet technology in the field of wound care. This was HydroCision's first Field-of-Use License for its technology.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Hydrocision competitors and assessment
Company assessmentBroad incumbents
- Arthrex: Dominant privately held sports medicine and orthopedic device company with broad MIS tenotomy, tendon repair, and arthroscopy portfolios. Competes directly with HydroCision's TenJet in treating chronic tendinopathy and overlaps on percutaneous spine access tools.
- Smith & Nephew: Global medtech incumbent with sports medicine, orthopedics, and advanced wound management franchises. Already a HydroCision licensee for wound care, S&N is also a competitor in MIS sports medicine tenotomy and competes across procedural categories.
- Stryker: Large diversified medical device company with deep spine, orthopedics, and sports medicine portfolios. Competes with HydroCision's SpineJet in MIS discectomy and adjacent tendon and sports medicine procedures through its endoscopy and spine divisions.
- Medtronic: Largest medical device company with a dominant spine surgery franchise (legacy Kyphon/including Covidien). HydroCision CEO and executives came from Covidien/Medtronic, and Medtronic's MIS discectomy and ablation tools compete with SpineJet.
- Becton Dickinson (BD): Major medical technology company with spine surgery and minimally invasive procedural products. Competes with HydroCision's SpineJet in discectomy and percutaneous access tools, and employs HydroCision alumni (Paul Kowalski) in its commercial ranks.
- Integra LifeSciences: Diversified medical device company with tissue technologies, orthopedics, and neurosurgery franchises. Overlaps with HydroCision in tissue processing (AlloJet) and sports medicine/extremities categories.
Direct peers
- Tenex Health (Tenex procedure): Direct competitor to HydroCision's TenJet in ultrasound-guided percutaneous tenotomy for chronic tendinopathy (tennis elbow, Achilles, plantar fasciitis). Targets the same orthopedic and sports medicine specialists with a similar minimally invasive outpatient procedure.
- Elliquence: Specialist in minimally invasive spine surgery technologies, including percutaneous discectomy and tissue modulation tools. Directly competes with HydroCision's SpineJet in treating contained disc herniations and MIS decompression.
Emerging players
- PROCEPT BioRobotics: Public surgical robotics company (NASDAQ: PRCT) commercializing Aquablation therapy for BPH using HydroCision-licensed FluidJet pump cartridge technology. Direct licensee and strategic commercial partner validating the FluidJet platform in urology.
- HistoSonics: Emerging non-invasive tissue ablation company using histotripsy (focused ultrasound) — an alternative non-thermal tissue destruction modality that could compete with HydroCision's non-thermal FluidJet in select indications over time.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Hydrocision social profiles
Digital presenceHydrocision financial estimates
Financial estimateRevenue estimate
Valuation estimate
Hydrocision leadership team
Management profileNumber of profiles
Profiles7 records
Hydrocision funding detail
Funding detailFunding overview
Funding rounds9 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Hydrocision M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Hydrocision
What does Hydrocision do?
HydroCision develops, manufactures, and markets minimally invasive surgical devices powered by its proprietary FluidJet technology — a high-velocity, non-thermal sterile saline stream that simultaneously cuts and aspirates targeted tissue. Its commercial product lines include the TenJet tenotomy device for chronic tendon conditions, the SpineJet PercResector for percutaneous discectomy, and the AlloJet allograft debridement system for tissue banks, sold primarily to hospitals and specialists in the United States. The company also licenses its core fluid-jet technology to partners in urology and wound care.
Is Hydrocision a public or private company?
Hydrocision is a private company. It is classified as venture growth investor backed and is currently operating.
When was Hydrocision founded?
Hydrocision was founded in 1994. It employs 11 to 50 people.
Where is Hydrocision based?
Hydrocision is headquartered in North Billerica, United States, in the North America region.
How does Hydrocision make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are technology Licensing and procedure Reimbursement.
Who are Hydrocision's main competitors?
Broad incumbents on record are Arthrex, Smith & Nephew, Stryker, Medtronic, Becton Dickinson (BD) and Integra LifeSciences. Direct peers are Tenex Health (Tenex procedure) and Elliquence. Emerging players are PROCEPT BioRobotics and HistoSonics.
Does Hydrocision have an API?
No public API is recorded for Hydrocision.
What industry is Hydrocision in?
Hydrocision's product category is Minimally Invasive Surgical Devices. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS), with a secondary code of HLAHADAM, Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits). Its NAICS code is 339112 and its SIC code is 3841.